These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16002531)

  • 21. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
    Funder JW
    Am Heart J; 2002 Nov; 144(5 Suppl):S8-11. PubMed ID: 12422135
    [No Abstract]   [Full Text] [Related]  

  • 22. Aldosterone and its blockade: a cardiovascular and renal perspective.
    Lahera V; Cachofeiro V; Balfagon G; Rodicio JL
    ScientificWorldJournal; 2006 Apr; 6():413-24. PubMed ID: 16604252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
    Nappi JM; Sieg A
    Vasc Health Risk Manag; 2011; 7():353-63. PubMed ID: 21731887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).
    Stier CT; Koenig S; Lee DY; Chawla M; Frishman WH
    Heart Dis; 2003; 5(2):102-18. PubMed ID: 12713678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.
    Davel AP; Jaffe IZ; Tostes RC; Jaisser F; Belin de Chantemèle EJ
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H989-H999. PubMed ID: 29957022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does Aldosterone Play a Significant Role for Regulation of Vascular Tone?
    Lyngsø KS; Assersen K; Dalgaard EG; Skott O; Jensen BL; Hansen PB
    J Cardiovasc Pharmacol; 2016 Jul; 68(1):1-10. PubMed ID: 26657712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
    Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
    Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aldosterone receptor antagonists.
    Azizi M
    Ann Endocrinol (Paris); 2021 Jun; 82(3-4):179-181. PubMed ID: 32473789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
    Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
    Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.
    Galuppo P; Bauersachs J
    Eur J Clin Invest; 2012 Oct; 42(10):1112-20. PubMed ID: 22536780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mineralocorticoids in the heart and vasculature: new insights for old hormones.
    Lother A; Moser M; Bode C; Feldman RD; Hein L
    Annu Rev Pharmacol Toxicol; 2015; 55():289-312. PubMed ID: 25251996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of aldosterone receptor blockade in the management of cardiovascular disease.
    Liew D; Krum H
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1468-73. PubMed ID: 12431020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aldosterone as a cardiovascular risk hormone.
    Yoshimoto T; Hirata Y
    Endocr J; 2007 Jun; 54(3):359-70. PubMed ID: 17409575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
    Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aldosterone, the Mineralocorticoid Receptor and Mechanisms of Cardiovascular Disease.
    Young MJ; Adler GK
    Vitam Horm; 2019; 109():361-385. PubMed ID: 30678863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-Genomic Effects of Aldosterone.
    Mihailidou AS; Tzakos AG; Ashton AW
    Vitam Horm; 2019; 109():133-149. PubMed ID: 30678853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mineralocorticoid receptor actions in cardiovascular development and disease.
    Young MJ; Clyne CD
    Essays Biochem; 2021 Dec; 65(6):901-911. PubMed ID: 34414409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldosterone and antialdosterone therapy in congestive heart failure.
    Weber KT; Villarreal D
    Am J Cardiol; 1993 Jan; 71(3):3A-11A. PubMed ID: 8422002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
    Tomaschitz A; Ritz E; Pieske B; Rus-Machan J; Kienreich K; Verheyen N; Gaksch M; Grübler M; Fahrleitner-Pammer A; Mrak P; Toplak H; Kraigher-Krainer E; März W; Pilz S
    Metabolism; 2014 Jan; 63(1):20-31. PubMed ID: 24095631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.